A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly developed form of CRISPR at UNSW Sydney points to a safer way of treating ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...

A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...

A glucose-sensitive nanovaccine delivers CRISPR to tumors, silences immune-suppressing genes, and activates a targeted immune response against cancer. (Nanowerk Spotlight) Immune-based cancer ...

The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

For the first time, scientists have found a way to efficiently and precisely remove genes from white blood cells of the immune system and to insert beneficial replacements, all in far less time than ...

Study in Molecular Therapy Oncology shows gene editing restores drug sensitivity by targeting NRF2, with potential across multiple tumor types In a major step forward for cancer care, researchers at ...

Gene editing is rewriting the future of medicine, as seen in the case of a baby named KJ Muldoon who got a fully personalised ...

Two studies published in Nature Medicine June 11 contribute to a small body of literature suggesting cells edited with CRISPR-Cas9 may cause cancer. Here are five things to know about the studies and ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ), scooping up 145,153 shares in the gene-editing play.